Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells

Liu,Zixin; Fan,Limei; Niu,Dongqin; Chen,Ming; Zhang,Weiran; Liu,Yuchen; Xu,Jinhua; Wang,Dong

doi:10.3892/or.2023.8607

Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells

Authors:
- Zixin Liu
- Limei Fan
- Dongqin Niu
- Ming Chen
- Weiran Zhang
- Yuchen Liu
- Jinhua Xu
- Dong Wang
View Affiliations

Affiliations: School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China, Wuhan Institute of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China
Published online on: July 27, 2023 https://doi.org/10.3892/or.2023.8607
Article Number: 170
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin (Oxa) is one of the most effective chemotherapeutic drugs used in the treatment of colorectal cancer (CRC). However, the use of this drug is associated with severe side‑effects and patients eventually develop resistance to Oxa. In recent years, copper complexes have been extensively investigated as substitutes for platinum‑based drugs. Therefore, a number of copper complexes have also been developed for cancer therapy, such as copper (II) complex of salicylate phenanthroline [Cu(sal)(phen)]. In the present study, the antitumor activity and the related molecular mechanisms of Cu(sal)(phen) were examined in CRC cells. As compared with the chemotherapeutic drug, Oxa, Cu(sal)(phen) was more effective in inducing apoptosis and reactive oxygen species (ROS) production, and in decreasing mitochondrial membrane potential in the CRC cell lines, HCT116 and SW480. In addition, the expression of the apoptosis‑related proteins, Bcl‑2 and survivin, and those of the upstream regulators, p‑JAK2 and p‑STAT5, were significantly decreased in the two cell lines following treatment with Cu(sal)(phen). Furthermore, the efficacy of the complex against CRC was found to be excellent in an animal model. The results of immunohistochemical analysis revealed that the expression levels of Bcl‑2, survivin and Ki‑67 in tumor tissues were decreased following Cu(sal)(phen) treatment. The antitumor mechanisms underlying Cu(Sal)(phen) treatment were the induction of ROS generation, the inhibition of the JAK2/STAT5 signaling pathway and the downregulation of the expression of anti‑apoptotic proteins, such as Bcl‑2 and survivin. On the whole, the findings of the present study indicated that Cu(sal)(phen) effectively inhibited the viability and proliferation of HCT116 and SW480 CRC cells; in the future, the authors aim to conduct further experiments in future studies to provide more evidence that supports the development of Cu(sal)(phen) as a therapeutic agent for CRC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Lu WQ, Hu YY, Lin XP and Fan W: Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells. Oncotarget. 8:44171–44185. 2017. View Article : Google Scholar : PubMed/NCBI
3	Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, et al: The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother. 137:1113642021. View Article : Google Scholar : PubMed/NCBI
4	Li Y, Sun Z, Cui Y, Zhang H, Zhang S, Wang X, Liu S and Gao Q: Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer. Bioorg Chem. 107:1046362021. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Lian W, Yuan Y and Li M: The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death Dis. 10:6002019. View Article : Google Scholar : PubMed/NCBI
6	Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M and Abad A: Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 14:1767–1776. 2015. View Article : Google Scholar : PubMed/NCBI
7	Buchholz A, Sahmoun AE and Kurniali PC: Characteristics of colorectal patients who discontinued oxaliplatin therapy. J Clin Oncol. 37 (Suppl):e151552019. View Article : Google Scholar
8	Zedan AH, Hansen TF, Svenningsen ÅF and Vilholm OJ: Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers. Clin Colorectal Cancer. 13:73–80. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ali A, Mishra S, Kamaal S, Alarifi A, Afzal M, Saha KD and Ahmad M: Evaluation of catacholase mimicking activity and apoptosis in human colorectal carcinoma cell line by activating mitochondrial pathway of copper(II) complex coupled with 2-(quinolin-8-yloxy)(methyl)benzonitrile and 8-hydroxyquinoline. Bioorg Chem. 106:1044792021. View Article : Google Scholar : PubMed/NCBI
10	Zehra S, Tabassum S and Arjmand F: Biochemical pathways of copper complexes: Progress over the past 5 years. Drug Discov Today. 26:1086–1096. 2021. View Article : Google Scholar : PubMed/NCBI
11	Song W, Xu P, Zhi S, Zhu S, Guo Y and Yang H: Integrated transcriptome and in vitro analysis revealed antiproliferative effects on human gastric cancer cells by a benzimidazole-quinoline copper(II) complex. Process Biochem. 102:286–295. 2021. View Article : Google Scholar
12	Sequeira D, Baptista PV, Valente R, Piedade MFM, Garcia MH, Morais TS and Fernandes AR: Cu(I) complexes as new antiproliferative agents against sensitive and doxorubicin resistant colorectal cancer cells: Synthesis, characterization, and mechanisms of action. Dalton Trans. 50:1845–1865. 2021. View Article : Google Scholar : PubMed/NCBI
13	Radhakrishnan K, Khamrang T, Sambantham K, Sali VK, Chitgupi U, Lovell JF, Mohammad AA and Venugopal R: Identification of cytotoxic copper(II) complexes with phenanthroline and quinoline, quinoxaline or quinazoline-derived mixed ligands. Polyhedron. 194:1148862021. View Article : Google Scholar
14	Mahendiran D, Kumar RS, Viswanathan V, Velmurugan D and Rahiman AK: Targeting of DNA molecules, BSA/c-Met tyrosine kinase receptors and anti-proliferative activity of bis(terpyridine)copper(ii) complexes. Dalton Trans. 45:7794–7814. 2016. View Article : Google Scholar : PubMed/NCBI
15	Gou Y, Chen M, Li S, Deng J, Li J, Fang G, Yang F and Huang G: Dithiocarbazate-copper complexes for bioimaging and treatment of pancreatic cancer. J Med Chem. 64:5485–5499. 2021. View Article : Google Scholar : PubMed/NCBI
16	Chen X, Dou QP, Liu J and Tang D: Targeting ubiquitin- proteasome system with copper complexes for cancer therapy. Front Mol Biosci. 8:6491512021. View Article : Google Scholar : PubMed/NCBI
17	Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR Jr, Yang DH and Chen ZS: Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 41:1–25. 2018. View Article : Google Scholar : PubMed/NCBI
18	Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV, Krasnov GS and Dmitriev AA: ROS generation and antioxidant defense systems in normal and malignant cells. Oxid Med Cell Longev. 2019:61758042019. View Article : Google Scholar : PubMed/NCBI
19	Ng CH, Kong SM, Tiong YL, Maah MJ, Sukram N, Ahmad M and Khoo ASB: Selective anticancer copper(II)-mixed ligand complexes: Targeting of ROS and proteasomes. Metallomics. 6:892–906. 2014. View Article : Google Scholar : PubMed/NCBI
20	Polloni L, Seni Silva AC, Teixeira SC, Azevedo FVPV, Zóia MAP, da Silva MS, Lima PMAP, Correia LIV, do Couto Almeida J, da Silva CV, et al: Action of copper(II) complex with β-diketone and 1,10-phenanthroline (CBP-01) on sarcoma cells and biological effects under cell death. Biomed Pharmacother. 112:1085862019. View Article : Google Scholar : PubMed/NCBI
21	Pfeffer CM and Singh ATK: Apoptosis: A target for anticancer therapy. Int J Mol Sci. 19:4482018. View Article : Google Scholar : PubMed/NCBI
22	Banjara S, Suraweera CD, Hinds MG and Kvansakul M: The Bcl-2 family: Ancient origins, conserved structures, and divergent mechanisms. Biomolecules. 10:1282020. View Article : Google Scholar : PubMed/NCBI
23	Sun BB, Fu LN, Wang YQ, Gao QY, Xu J, Cao ZJ, Chen YX and Fang JY: Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. J Dig Dis. 15:491–500. 2014. View Article : Google Scholar : PubMed/NCBI
24	Li D, Hu C and Li H: Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep. 8:399–406. 2018.PubMed/NCBI
25	de Ridder I, Kerkhofs M, Veettil SP, Dehaen W and Bultynck G: Cancer cell death strategies by targeting Bcl-2′s BH4 domain. Biochim Biophys Acta Mol Cell Res. 1868:1189832021. View Article : Google Scholar : PubMed/NCBI
26	Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, et al: Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res. 19:631–642. 2013. View Article : Google Scholar : PubMed/NCBI
27	Lopes JC, Botelho FV, Barbosa Silva MJ, Silva SF, Polloni L, Alves Machado PH, Rodrigues de Souza T, Goulart LR, Silva Caldeira PP, Pereira Maia EC, et al: In vitro and in vivo antitumoral activity of a ternary copper (II) complex. Biochem Biophys Res Commun. 533:1021–1026. 2020. View Article : Google Scholar : PubMed/NCBI
28	Fan L, Tian M, Liu Y, Deng Y, Liao Z and Xu J: Salicylate •phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells. Oncotarget. 8:29823–29832. 2017. View Article : Google Scholar : PubMed/NCBI
29	Sukhdeo K, Paramban RI, Vidal JG, Elia J, Martin J, Rivera M, Carrasco DR, Jarrar A, Kalady MF, Carson CT, et al: Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One. 8:e530152013. View Article : Google Scholar : PubMed/NCBI
30	Kreutz D, Bileck A, Plessl K, Wolrab D, Groessl M, Keppler BK, Meier SM and Gerner C: Response profiling using shotgun proteomics enables global metallodrug mechanisms of action to be established. Chemistry. 23:1881–1890. 2017. View Article : Google Scholar : PubMed/NCBI
31	Sun W, Ge Y, Cui JP, Yu YF and Liu BL: Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Mol Ther Oncolytics. 21:87–97. 2021. View Article : Google Scholar : PubMed/NCBI
32	Guo WJ, Ye SS, Cao N, Huang JA, Gao J and Chen QY: ROS-mediated autophagy was involved in cancer cell death induced by novel copper(II) complex. Exp Toxicol Pathol. 62:577–582. 2010. View Article : Google Scholar : PubMed/NCBI
33	Cao Y, Wang J, Tian H and Fu GH: Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res. 39:1192020. View Article : Google Scholar : PubMed/NCBI
34	Murphy MP: How mitochondria produce reactive oxygen species. Biochem J. 417:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
35	Warren CFA, Wong-Brown MW and Bowden NA: BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 10:1772019. View Article : Google Scholar : PubMed/NCBI
36	Peery RC, Liu JY and Zhang JT: Targeting survivin for therapeutic discovery: Past, present, and future promises. Drug Discov Today. 22:1466–1477. 2017. View Article : Google Scholar : PubMed/NCBI
37	Jiang F, Zhou JY, Zhang D, Liu MH and Chen YG: Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate-induced apoptosis. Int J Mol Med. 42:1295–1304. 2018.PubMed/NCBI
38	Schütz CS, Stope MB and Bekeschus S: H2A.X phosphorylation in oxidative stress and risk assessment in plasma medicine. Oxid Med Cell Longev. 2021:20609862021. View Article : Google Scholar : PubMed/NCBI
39	Johnstone TC, Suntharalingam K and Lippard SJ: The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 116:3436–3486. 2016. View Article : Google Scholar : PubMed/NCBI
40	Gałczyńska K, Drulis-Kawa Z and Arabski M: Antitumor activity of Pt(II), Ru(III) and Cu(II) complexes. Molecules. 25:34922020. View Article : Google Scholar : PubMed/NCBI
41	Wang NN, Zhang PZ, Zhang J, Wang HN, Li L, Ren F, Dai PF, Li H and Lv XF: Penfluridol triggers mitochondrial-mediated apoptosis and suppresses glycolysis in colorectal cancer cells through down-regulating hexokinase-2. Anat Rec (Hoboken). 304:520–530. 2021. View Article : Google Scholar : PubMed/NCBI
42	Cui Q, Wen S and Huang P: Targeting cancer cell mitochondria as a therapeutic approach: Recent updates. Future Med Chem. 9:929–949. 2017. View Article : Google Scholar : PubMed/NCBI
43	Kleih M, Böpple K, Dong M, Gaißler A, Heine S, Olayioye MA, Aulitzky WE and Essmann F: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 10:8512019. View Article : Google Scholar : PubMed/NCBI
44	Xia S, Miao Y and Liu S: Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells. Biochem Biophys Res Commun. 503:2363–2369. 2018. View Article : Google Scholar : PubMed/NCBI
45	Kowol CR, Heffeter P, Miklos W, Gille L, Trondl R, Cappellacci L, Berger W and Keppler BK: Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. J Biol Inorg Chem. 17:409–423. 2012. View Article : Google Scholar : PubMed/NCBI
46	Basak D, Uddin MN and Hancock J: The role of oxidative stress and its counteractive utility in colorectal cancer (CRC). Cancers (Basel). 12:33362020. View Article : Google Scholar : PubMed/NCBI
47	Moloney JN and Cotter TG: ROS signalling in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
48	Yang F, Pei R, Zhang Z, Liao J, Yu W, Qiao N, Han Q, Li Y, Hu L, Guo J, et al: Copper induces oxidative stress and apoptosis through mitochondria-mediated pathway in chicken hepatocytes. Toxicol In vitro. 54:310–316. 2019. View Article : Google Scholar : PubMed/NCBI
49	Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, et al: Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022. View Article : Google Scholar : PubMed/NCBI
50	Piché A, Grim J, Rancourt C, Gómez-Navarro J, Reed JC and Curiel DT: Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:2134–2140. 1998.PubMed/NCBI
51	Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S and Tamura T: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 68:505–511. 2011. View Article : Google Scholar : PubMed/NCBI
52	Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y and Kong D: Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget. 8:28906–28921. 2017. View Article : Google Scholar : PubMed/NCBI
53	Niu D, Wang D, Fan L, Liu Z, Chen M, Zhang W and Liu Y, Xu J and Liu Y: The copper (II) complex of salicylate phenanthroline inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Environ Toxicol. 38:1384–1394. 2023. View Article : Google Scholar : PubMed/NCBI